Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – CNS tumours

2990 - Circulating PD-L1 levels vary across brain tumor entities and are oppositely linked to survival in glioblastoma and lower grade glioma patients

Date

28 Sep 2019

Session

Poster Discussion – CNS tumours

Presenters

Maximilian Mair

Citation

Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243

Authors

M. Mair1, A. Ilhan-Mutlu1, S. Pajenda2, G. Widhalm3, K. Dieckmann4, J.A. Hainfellner5, C. Marosi1, L. Wagner2, M. Preusser1, A.S. Berghoff1

Author affiliations

  • 1 Department Of Medicine I, Medical University of Vienna, 1090 - Vienna/AT
  • 2 Department Of Medicine Iii, Medical University of Vienna, 1090 - Vienna/AT
  • 3 Department Of Neurosurgery, Medical University of Vienna, 1090 - Vienna/AT
  • 4 Department Of Radiotherapy, Medical University of Vienna, 1090 - Vienna/AT
  • 5 Institute Of Neurology, Medical University of Vienna, 1090 - Vienna/AT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2990

Background

Immune therapies targeting the programmed cell death receptor (ligand) 1 (PD-1/PD-L1) axis have shown remarkable activity in a variety of solid tumors. While substantial responses were observed in asymptomatic patients with brain metastases (BM), their clinical activity in primary brain tumors remains limited. In a cohort of adult brain tumor patients, we aimed to analyze soluble PD-L1 (sPD-L1) levels in patient plasma as a systemic marker of tumor - immune system interactions.

Methods

We obtained EDTA plasma from 55 glioblastoma, 26 lower-grade (WHO grade II - III) glioma (LGG), 17 meningioma and 43 BM patients (29/43 lung cancer, 6/43 renal cell carcinoma, 4/43 breast cancer, 4/43 melanoma) as well as 25 controls. sPD-L1 concentrations were measured by a sandwich ELISA using an anti-PD-L1/CD274 antibody (Millipore ABF133) as capture antibody and a non-commercial anti-PD-L1 antibody (clone 5H1) as detection antibody. The lower detection limit as determined by serial dilutions of recombinant human PD-L1 was 0.050 ng/ml.

Results

sPD-L1 was identified in 41/81 (50.6%) glioma, 5/17 (29.4%) meningioma and 6/43 (14.0%) BM patient samples and in 9/25 (36.0%) controls (p = 0.001, Chi-square), with a median concentration of 0.415 ng/ml (range: 0.050 – 42.150 ng/ml). sPD-L1 concentrations were significantly lower in BM as compared to glioma patients (p < 0.001, Mann-Whitney-U) or controls (p = 0.028). There was no observable difference in sPD-L1 concentrations and detectability over WHO grades in glioma and meningioma patients. In BM patients, a trend towards different sPD-L1 levels between primary tumors was seen (p = 0.122, Kruskal-Wallis). sPD-L1 was not correlated to prognosis in meningioma and BM patients. In contrast, glioblastoma patients had longer overall survival (OS) when sPD-L1 was detected (p = 0.006, log-rank). Conversely, sPD-L1 detectability was linked to worse OS in LGG (p = 0.028).

Conclusions

Circulating PD-L1 levels differ between patients with distinct CNS malignancies, suggesting diverse tumor - immune system interactions between primary and secondary brain tumors. Moreover, our results indicate a differential prognostic impact of sPD-L1 in glioma which should be further studied.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Medical University of Vienna.

Disclosure

A. Ilhan-Mutlu: Advisory / Consultancy: MSD; Advisory / Consultancy: Servier. M. Preusser: Research grant / Funding (self): Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): GlaxoSmithKline; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Gerson Lehrman Group (GLG); Honoraria (self), Advisory / Consultancy: CMC Contrast; Honoraria (self), Advisory / Consultancy: Mundipharma; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: AbbVie; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Medahead; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo. A.S. Berghoff: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AbbVie. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.